Table 1.
Summary of the 14 observational studies assessing the treatment outcomes for patients with MDR-TB under DOTS-Plus that were included in the meta-analysis (n = 14)
| Study authors | Study location | Study period | Study design | Sample size | HIV (%) | Treatment duration | Treatment regimen |
|---|---|---|---|---|---|---|---|
| Kurbatova et al. [16] | Five countriesa | 2000–2003 | RC | 1768 | 1.6 | Individualized | |
| Singla et al. [17] | India | 2002–2006 | RC | 126 | – | 24–27 months | Standardized |
| Keshavjee et al. [18] | Russia | 2000–2004 | RC | 579 | 0.9 | ≥24 months | Individualized |
| Riekstina et al. [19] | Latvia | 2002 | RC | 75 | – | 24 months | Individualized |
| Cox et al. [20] | Karakalpakstan, Uzbekistan | 2003–2005 | PC | 87 | – | ≥24 months | Individualized |
| Shin et al. [21] | Russia | 2000–2002 | RC | 244 | 0 | ≥12 months | Individualized |
| Holtz et al. [22] | Latvia | 2000 | RC | 167 | – | 12–18 months after conversion | Individualized |
| Leimane et al. [23] | Latvia | 2000 | RC | 204 | 0.5 | 12–18 months after conversion | Individualized |
| Tupasi et al. [24] | Philippines | 1999–2002 | PC | 149 | – | ≥24 Months | Individualized |
| Arora et al. [25] | India | 2002–2005 | RC | 52 | – | 24 months | Standardized |
| Mitnick et al. [26] | Peru | 1999–2002 | RC | 651 | 1.5 | 15 months after conversion | Standardized |
| Jain et al. [27] | India | 2009 | PC | 130 | – | 24 months | Standardized |
| Farley et al. [28] | South Africa | 2000–2004 | PC | 757 | 38 | 12–18 months after conversion | Standardized |
| Van Deun et al. [14] | Bangladesh | 1997–1999 | RC | 58 | – | 24 months | Standardized |
aThe five countries were Peru, Latvia, Estonia, Russia, and the Philippines